Open access

1148 A listeriolysin O-CD47 protein-antibody conjugate triggers cGAS-STING activation in solid tumor malignancies
Abin Antony, Benjamin R Schrank, Yifan Wang, Wen Jiang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1264; DOI: 10.1136/jitc-2023-SITC2023.1148
1149 Sensitizing aggressive murine pancreatic cancer to immune checkpoint blockade using a tumor-targeted, STING agonist ‘payloaded’ antibody
Akash Boda, Shweta Hegde, Sean Smith, Michael Curran

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1265; DOI: 10.1136/jitc-2023-SITC2023.1149
1150 DM005, an EGFR × MET bispecific antibody-drug conjugate, showed robust anti-tumor activity in PDX models
Yanfei Han, Wenjuan Dai, Chengzhang Shang, Zhuolin Li, Zhenyan Han, Jun Li, Zixu Cui, Gao An, Wanjun Hao, Yujie Liu, Hao Li, Baihong Liu, W Frank An, Chaoshe Guo, Yi Yang, Yuelei Shen

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1266; DOI: 10.1136/jitc-2023-SITC2023.1150
1151 Antibody-drug conjugates targeting CLDN18.2 for the treatment of solid tumors
Xiaoyao Hao, Jinyu Liu, Xiaodong F Liu, Hongyan Li, Jun Li, Wenwen Dai, Qun Lv, Shukai Xia, Mark Z Ma, Mingjiu Chen, Zeyu Peng

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1267; DOI: 10.1136/jitc-2023-SITC2023.1151
1152 DM001: A novel bispecific ADC targeting TROP2 and EGFR with potent anti-tumor efficacy in PDX models
Zhuolin Li, Chengzhang Shang, Xuewa Guan, Gao An, Yuming Guo, W Frank An, Chaoshe Guo, Yi Yang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1268; DOI: 10.1136/jitc-2023-SITC2023.1152
1153 BCG022: a HER3×MET bispecific antibody-drug conjugate (BsADC) targeting key mechanisms of bypass resistance in multiple tumor types
Zhuolin Li, Chengzhang Shang, Zhenyan Han, Gao An, W Frank An, Chaoshe Guo, Yi Yang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1269; DOI: 10.1136/jitc-2023-SITC2023.1153
1154 Anti-PD-L1 antibody-immune modulator conjugates significantly enhance anti-tumor activity in syngeneic models
Soyeon Lim, Yun-Hee Park, Myeong Joo Kim, Na Ra Han, Ho Young Song, Chul-Woong Chung

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1270; DOI: 10.1136/jitc-2023-SITC2023.1154
1155 Activated regulatory T cells in solid tumors express CD30, which are selectively targeted by the novel anti-CD30 antibody drug conjugate SGN-35T
Brian P O’Connor, Bryan M Grogan, Reice D James, Michelle L Ulrich, Jason D Berndt, Hailing Lu, Melissa Conerly, Astrid Clarke, Kevin J Hamblett, Ryan A Heiser

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1271; DOI: 10.1136/jitc-2023-SITC2023.1155
1156 Improved anti-ovarian cancer effectiveness of HER2-directing ADC via engineering with a super-hydrophilic PMPC polymer
Jie Ren, Chloe E Jepson, Stella U Azolibe, Charles J Kuhlmann, Madison T Blucas, Yoshiko N Kamata, Masakazu Kamata

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1272; DOI: 10.1136/jitc-2023-SITC2023.1156
1157 GQ1007: the next generation HER2-targeting antibody immune agonist conjugate with robust efficacy and favorable safety profile
Paul Song, Lily Shi, Chong Liu, Yajun Sun, Beibei Fan, Hanwen Xu, Gang Qin

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1273-A1276; DOI: 10.1136/jitc-2023-SITC2023.1157

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages